Following discharge for acute coronary syndrome (heart attack or unstable angina), patients are typically treated with dual antiplatelet
therapy for around one year.
(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that pharmacodynamic data from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet
drug ticagrelor, have been selected for oral presentation at ESC Congress 2019, being held August 31 - September 4, 2019, at the Expo Porte de Versailles in Paris, France.
[USPRwire, Thu Jul 11 2019] Although the dual antiplatelet
therapy reduces the risks of thromboembolic conditions, it is also associated with a major risk of bleeding that can sometimes be fatal, which may create hindrance in the growth of dual antiplatelet
Summary: Dual antiplatelet
therapy is defined as the use of aspirin and P2Y12 receptor inhibitor to prevent blood clotting, and through a double mechanism, it prevents thrombotic complications.
NNA - The Lebanese Society of Cardiology (LSC) has launched a mobile phone application that allows medical doctors to access a clear algorithm on Oral Antiplatelet
(OAP) therapy and determine individualized regimens for patients at risk of Acute Coronary Syndrome (ACS), an umbrella term encompassing a number of conditions including unstable angina and myocardial infarction.
Platelet research company Aggredyne Inc revealed on Monday the receipt of clearance from the US Food and Drug Administration (FDA) for its AggreGuide A-100 ADP Assay testing cartridge that is used to measure the effect of various antiplatelet
PhaseBio Pharmaceuticals announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet
drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet
effects without report of drug-related serious adverse events.
However, whether antiplatelet
therapy could prevent the development of ischemic stroke and myocardial infarction remained unknown.
Aspirin is an essential part of dual antiplatelet
therapy in and it is strongly indicated in secondary prevention of cardiovascular diseases.
therapy is the mainstay of secondary stroke prevention.